Here is a summary of the clinical data supporting CT-868: Safety and Tolerability : The Phase 1 trial in participants with overweight and obesity showed that CT-868 doses up to 11 mg in single ascending dose (SAD) and 5 mg in multiple ascending dose (MAD) portions were safe and tolerable, supporting its advancement into Phase 2 trials
The rationale of this work was to conclude if dulaglutide (Dula) could protect rats from developing colitis caused by exposure to acetic acid (AA)
Talk to your healthcare provider about appealing the insurance companys decision
If you have heart problems, liver problems, kidney problems, bleeding problems, low levels of sodium, or bipolar disorder, make sure to tell your doctor so they can recommend the appropriate treatment plan for you
Dual-action GLP-1/GIP receptor agonists like Zepbound can also mimic the action of GIP, a hormone that helps regulate blood sugar levels and metabolism
Both Novo Nordisk and Eli Lilly now offer manufacturer self-pay programs that dramatically reduce the GLP-1 cost without insurance
